These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 23630200)

  • 1. Cediranib for metastatic alveolar soft part sarcoma.
    Kummar S; Allen D; Monks A; Polley EC; Hose CD; Ivy SP; Turkbey IB; Lawrence S; Kinders RJ; Choyke P; Simon R; Steinberg SM; Doroshow JH; Helman L
    J Clin Oncol; 2013 Jun; 31(18):2296-302. PubMed ID: 23630200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS).
    Cohen JW; Widemann BC; Derdak J; Dombi E; Goodwin A; Dompierre J; Onukwubiri U; Steinberg SM; O'Sullivan Coyne G; Kummar S; Chen AP; Glod J
    Pediatr Blood Cancer; 2019 Dec; 66(12):e27987. PubMed ID: 31502400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.
    Judson I; Morden JP; Kilburn L; Leahy M; Benson C; Bhadri V; Campbell-Hewson Q; Cubedo R; Dangoor A; Fox L; Hennig I; Jarman K; Joubert W; Kernaghan S; López Pousa A; McNeil C; Seddon B; Snowdon C; Tattersall M; Toms C; Martinez Trufero J; Bliss JM
    Lancet Oncol; 2019 Jul; 20(7):1023-1034. PubMed ID: 31160249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma.
    Nguyen J; Takebe N; Kummar S; Razak A; Chawla SP; George S; Patel SR; Keohan ML; Movva S; O'Sullivan Coyne G; Do K; Juwara L; Augustine B; Steinberg SM; Kuhlmann L; Ivy SP; Doroshow JH; Chen AP
    Clin Cancer Res; 2023 Apr; 29(7):1200-1208. PubMed ID: 36302173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.
    Judson I; Scurr M; Gardner K; Barquin E; Marotti M; Collins B; Young H; Jürgensmeier JM; Leahy M
    Clin Cancer Res; 2014 Jul; 20(13):3603-12. PubMed ID: 24714778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.
    Sridhar SS; Mackenzie MJ; Hotte SJ; Mukherjee SD; Tannock IF; Murray N; Kollmannsberger C; Haider MA; Chen EX; Halford R; Wang L; Ivy SP; Moore MJ
    Invest New Drugs; 2013 Aug; 31(4):1008-15. PubMed ID: 23354849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect.
    Stacchiotti S; Negri T; Zaffaroni N; Palassini E; Morosi C; Brich S; Conca E; Bozzi F; Cassinelli G; Gronchi A; Casali PG; Pilotti S
    Ann Oncol; 2011 Jul; 22(7):1682-1690. PubMed ID: 21242589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.
    Kim M; Kim TM; Keam B; Kim YJ; Paeng JC; Moon KC; Kim DW; Heo DS
    Oncologist; 2019 Jan; 24(1):20-e29. PubMed ID: 30254189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
    van Cruijsen H; Voest EE; Punt CJ; Hoekman K; Witteveen PO; Meijerink MR; Puchalski TA; Robertson J; Saunders O; Jürgensmeier JM; van Herpen CM; Giaccone G
    Eur J Cancer; 2010 Mar; 46(5):901-11. PubMed ID: 20061136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.
    Schöffski P; Wozniak A; Kasper B; Aamdal S; Leahy MG; Rutkowski P; Bauer S; Gelderblom H; Italiano A; Lindner LH; Hennig I; Strauss S; Zakotnik B; Anthoney A; Albiges L; Blay JY; Reichardt P; Sufliarsky J; van der Graaf WTA; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Raveloarivahy T; Collette S; Stacchiotti S
    Ann Oncol; 2018 Mar; 29(3):758-765. PubMed ID: 29216400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer.
    Satoh T; Yamaguchi K; Boku N; Okamoto W; Shimamura T; Yamazaki K; Shi X; Mishima H
    Invest New Drugs; 2012 Aug; 30(4):1511-8. PubMed ID: 21611734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
    Hong DS; Garrido-Laguna I; Ekmekcioglu S; Falchook GS; Naing A; Wheler JJ; Fu S; Moulder SL; Piha-Paul S; Tsimberidou AM; Wen Y; Culotta KS; Anderes K; Davis DW; Liu W; George GC; Camacho LH; Percy Ivy S; Kurzrock R
    Cancer; 2014 Jul; 120(14):2164-73. PubMed ID: 24752867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib.
    Li T; Wang L; Wang H; Zhang S; Atikan Kawuli ; Zhang X; Luo Z; Wang C
    Invest New Drugs; 2016 Dec; 34(6):701-706. PubMed ID: 27604635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review.
    Paoluzzi L; Maki RG
    JAMA Oncol; 2019 Feb; 5(2):254-260. PubMed ID: 30347044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
    Liu JF; Tolaney SM; Birrer M; Fleming GF; Buss MK; Dahlberg SE; Lee H; Whalen C; Tyburski K; Winer E; Ivy P; Matulonis UA
    Eur J Cancer; 2013 Sep; 49(14):2972-8. PubMed ID: 23810467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
    Batchelor TT; Duda DG; di Tomaso E; Ancukiewicz M; Plotkin SR; Gerstner E; Eichler AF; Drappatz J; Hochberg FH; Benner T; Louis DN; Cohen KS; Chea H; Exarhopoulos A; Loeffler JS; Moses MA; Ivy P; Sorensen AG; Wen PY; Jain RK
    J Clin Oncol; 2010 Jun; 28(17):2817-23. PubMed ID: 20458050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.
    Mulders P; Hawkins R; Nathan P; de Jong I; Osanto S; Porfiri E; Protheroe A; van Herpen CM; Mookerjee B; Pike L; Jürgensmeier JM; Gore ME
    Eur J Cancer; 2012 Mar; 48(4):527-37. PubMed ID: 22285180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Much Ado about ASPS: The Rapidly Changing Treatment Paradigms of 2022.
    Wilky BA; Maleddu A
    Clin Cancer Res; 2023 Apr; 29(7):1163-1166. PubMed ID: 36692840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies.
    Groisberg R; Roszik J; Conley AP; Lazar AJ; Portal DE; Hong DS; Naing A; Herzog CE; Somaiah N; Zarzour MA; Patel S; Brown RE; Subbiah V
    Mol Cancer Ther; 2020 May; 19(5):1165-1172. PubMed ID: 32127467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
    Yamamoto N; Tamura T; Yamamoto N; Yamada K; Yamada Y; Nokihara H; Fujiwara Y; Takahashi T; Murakami H; Boku N; Yamazaki K; Puchalski TA; Shin E
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1165-72. PubMed ID: 19308410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.